Optimizing anti-TNF treatment in inflammatory bowel disease
Top Cited Papers
- 1 May 2004
- journal article
- review article
- Published by Elsevier in Gastroenterology
- Vol. 126 (6) , 1593-1610
- https://doi.org/10.1053/j.gastro.2004.02.070
Abstract
No abstract availableKeywords
This publication has 90 references indexed in Scilit:
- Infliximab Maintenance Therapy for Fistulizing Crohn's DiseaseNew England Journal of Medicine, 2004
- Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart FailureCirculation, 2003
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialPublished by Elsevier ,2002
- Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's diseaseGut, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitisPublished by Elsevier ,1999
- Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.Gut, 1996
- Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea.Journal of Clinical Pathology, 1993
- Treatment of Crohn's Disease with 6-MercaptopurineNew England Journal of Medicine, 1980